Human placental-derived stem cell therapy ameliorates experimental necrotizing enterocolitis.

Area of Science:

• Neonatal Medicine
• Gastroenterology
• Stem Cell Therapy

Background:

• Necrotizing enterocolitis (NEC) is a critical intestinal disease in premature infants with limited therapeutic options.
• Human placental-derived stem cells (hPSC) have shown potential in regenerative medicine.
• Investigating hPSC as a therapeutic for NEC is crucial due to its high morbidity and mortality.

Purpose of the Study:

• To evaluate the efficacy of human placental-derived stem cell (hPSC) therapy in an experimental model of necrotizing enterocolitis (NEC).
• To assess the impact of hPSC on intestinal damage, epithelial integrity, and stem cell populations in NEC.
• To explore hPSC as a potential therapeutic strategy for NEC.

Main Methods:

• An experimental NEC rat pup model was established using formula feeding, hypoxia, and LPS.
• NEC pups received intraperitoneal injections of either saline or hPSC.
• Intestinal damage, epithelial cell composition, and inflammatory markers were assessed post-treatment.

Main Results:

• hPSC treatment significantly improved macroscopic intestinal health, reducing ileal dilation and fragility.
• Histological analysis revealed hPSC administration repaired villi-crypt morphology and epithelium.
• hPSC therapy increased epithelial proliferation, decreased apoptosis, and restored the intestinal stem cell niche.

Conclusions:

• Human placental-derived stem cells (hPSC) demonstrate a significant therapeutic effect on established intestinal damage in a necrotizing enterocolitis (NEC) model.
• hPSC promote epithelial healing and support the intestinal stem cell niche, offering a potential treatment for NEC.
• hPSC serve as a valuable research tool to understand neonatal intestinal repair mechanisms.